Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions-Reference-Cited by-同舟云学术

Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions

Published:2016-11-22 Issue:sup2 Volume:15 Page:51-59
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Sessa Maurizio¹,Rossi Claudia²,Rafaniello Concetta¹,Mascolo Annamaria¹,Cimmaruta Daniela¹,Scavone Cristina¹,Fiorentino Sonia¹,Grassi Enrico²,Reginelli Alfonso²,Rotondo Antonio²,Sportiello Liberata¹

Affiliation:

1. Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Second University of Naples, Naples, Italy

2. Department of Internal and Experimental Medicine, ‘Magrassi-Lanzara,’ Institute of Radiology, Second University of Naples, Naples, Italy

Funder

Second University of Naples

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2016.1226280

Reference23 articles.

1. European Medicine Agency. Identification of preventable adverse drug reactions from a regulatory perspective [cited 2016 May 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/03/WC500139874.pdf

2. The Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project

3. Preventability of Drug-Related Harms – Part I

4. Preventability of Drug-Related Harms – Part II

5. Assessment of a New Instrument for Detecting Preventable Adverse Drug Reactions

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing;Drug Safety;2023-12-07

2. Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines;Frontiers in Cardiovascular Medicine;2023-11-24

3. Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data;Drug Safety;2023-06-10

4. Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies;Expert Opinion on Drug Safety;2023-01-02

5. Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System;Frontiers in Pharmacology;2019-04-30